Home › A risky biotech stock's rise and fall
 

Keywords :   


A risky biotech stock's rise and fall

2015-03-14 00:32:54| Biotech - Topix.net

Biotech firm Neuralstem's stock sank by 37% Thursday, to $2.37 a share, after it reported disappointing results from a clinical trial. In January 2014, a 41-year-old mother named April Moundzouris who had been diagnosed with amyotrophic lateral sclerosis, or Lou Gehrig's disease, blogged that she was responding well to treatment in a clinical trial.

Tags: fall rise stocks biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
05.11Shoppers warned over luxury advent calendar scams
05.11Durable Floor Coating from HMG Paints Transforms FC United\'s SMRE Bar
05.11Teknos Poland Honored by Farby i Lakiery
05.11Xumo teams up with Target to offer Hisense Xumo TVs
05.11KT launches 8K AI-powered IPTV set-top box
05.11Tropical Storm Rafael Graphics
More »